Phase 2Recruiting
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
- Sponsor
- Alliance for Clinical Trials in Oncology (Academic or other)
- Enrollment
- 474 planned
- Conditions
- Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Genetic testing; Valemetostat Tosylate; Magnetic Resonance Imaging; Computed Tomography; Bone scan; FDG-Positron Emission Tomography; PSMA PET Scan; Biospecimen Collection; Carboplatin; Cabazitaxel; Abiraterone Acetate; Enzalutamide
- Ages
- adults, older adults
- Registry
- NCT06632977
Full record on ClinicalTrials.gov
From the registry
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type…
Primary outcomes
- Objective Response
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered